Targeting resistance in cancer with double imprinted polymers as drug delivery nano vehicles

At present, doctors need to wait about three months after beginning treatment for lung cancer to be able to tell if it is working. Moreover, there are limited treatment options available for those with resistant lung cancer.

In this project, we will develop engineered biomaterials to deliver drugs directly to the resistant lung cancer cells. We will move away from antibodies, which are considered the "gold standard" for drug development but are costly and cause unwanted reactions. Novel polymer materials will be produced that can specifically target cancer cells, which will improve patient outcome and limit harmful side effects of treatment.

This project builds on our targeted approach for drug delivery, in this case for breast cancer, which can be found here: https://www.biorxiv.org/content/10.1101/2023.07.19.549711v1